Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Johnson

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Current Medical Research and Opinion|September 6, 2017
Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitorsAllan Gibofsky, Martha Skup, Manish Mittal, et al.
Inflammatory Bowel Diseases|September 18, 2010
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Si-Tien Wang, et al.
Advances in Therapy|November 5, 2017
Changes in Healthcare Spending After Diagnosis of Comorbidities Among Endometriosis Patients: A Difference-in-Differences AnalysisAndrew J Epstein, Ahmed M Soliman, Matthew Davis, et al.
Journal of Comparative Effectiveness Research|February 7, 2019
Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USASi-Tien Wang, Scott J Johnson, Dominic Mitchell, et al.
European Journal of Gastroenterology & Hepatology|May 26, 2009
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Andrew P Yu, et al.
Journal of Women'S Health (2002)|August 3, 2018
Risk of Developing Comorbidities Among Women with Endometriosis: A Retrospective Matched Cohort StudyEric S Surrey, Ahmed M Soliman, Scott J Johnson, et al.
Journal of the American Geriatrics Society|September 14, 2013
Effects of care management and telehealth: a longitudinal analysis using medicare dataLaurence C Baker, Dendy S Macaulay, Rachael A Sorg, et al.
Pharmacoeconomics|August 3, 2013
Costs of Parkinson's disease in a privately insured populationScott J Johnson, Anna Kaltenboeck, Melissa Diener, et al.
Journal of Ophthalmic Inflammation and Infection|November 8, 2013
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USADavid S Chu, Scott J Johnson, Usha G Mallya, et al.
Pharmacoeconomics|March 29, 2008
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetesScott D Ramsey, Lauren D Clarke, Craig S Roberts, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Current Medical Research and Opinion|September 6, 2017
Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitorsAllan Gibofsky, Martha Skup, Manish Mittal, et al.
Inflammatory Bowel Diseases|September 18, 2010
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Si-Tien Wang, et al.
Advances in Therapy|November 5, 2017
Changes in Healthcare Spending After Diagnosis of Comorbidities Among Endometriosis Patients: A Difference-in-Differences AnalysisAndrew J Epstein, Ahmed M Soliman, Matthew Davis, et al.
Journal of Comparative Effectiveness Research|February 7, 2019
Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USASi-Tien Wang, Scott J Johnson, Dominic Mitchell, et al.
European Journal of Gastroenterology & Hepatology|May 26, 2009
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Andrew P Yu, et al.
Journal of Women'S Health (2002)|August 3, 2018
Risk of Developing Comorbidities Among Women with Endometriosis: A Retrospective Matched Cohort StudyEric S Surrey, Ahmed M Soliman, Scott J Johnson, et al.
Journal of the American Geriatrics Society|September 14, 2013
Effects of care management and telehealth: a longitudinal analysis using medicare dataLaurence C Baker, Dendy S Macaulay, Rachael A Sorg, et al.
Pharmacoeconomics|August 3, 2013
Costs of Parkinson's disease in a privately insured populationScott J Johnson, Anna Kaltenboeck, Melissa Diener, et al.
Journal of Ophthalmic Inflammation and Infection|November 8, 2013
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USADavid S Chu, Scott J Johnson, Usha G Mallya, et al.
Pharmacoeconomics|March 29, 2008
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetesScott D Ramsey, Lauren D Clarke, Craig S Roberts, et al.
Pageof 3